In July 2011, the U.S. Food and Drug Administration (FDA) released a white paper [1] and safety communication [2] on the safety and effectiveness of transvaginal placement of surgical mesh for pelvic organ prolapse. Since then, some state medical organizations, healthcare systems, and insurance companies have considered, or adopted, complete restrictions on the use of transvaginal mesh for pelvic organ prolapse or stress urinary incontinence.
Read More